You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 41 No. 11, November 1984 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (36)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Anticholinergic Challenge and Neuroleptic Withdrawal

Changes in Dyskinesia and Symptom Measures

George Gardos, MD; Jonathan O. Cole, MD; Robert M. Rapkin, MD; Richard A. LaBrie, PhD; Eleanor Baquelod, RN; Patricia Moore, RN, MPH; Robert Sovner, MD; John Doyle, RN

Arch Gen Psychiatry. 1984;41(11):1030-1035.


Abstract



• Benztropine mesylate (intravenous [IV] and oral) challenge was compared with brief neuroleptic withdrawal on dyskinesia ratings and symptom measures. Thirty-six neuroleptic-treated patients underwent a placebo-controlled acute IV challenge with 2 mg benztropine and a placebocontrolled two-week trial of oral benztropine mesylate (2 mg three times a day), followed by a double-blind placebo-controlled neuroleptic withdrawal involving four weeks of dose tapering and six weeks of placebo treatment. Benztropine given IV had no significant effect. Orally administered benztropine, however, led to statistically significant increases in dyskinesia and dysphoric mood. The brief neuroleptic withdrawal significantly increased dyskinesia scores and dysphoria and resulted in early termination of therapy in 12 of 36 patients (33%) due to symptom exacerbation. There was a striking absence of correlation between dyskinesia change measures brought about by benztropine and changes following neuroleptic withdrawal. Therefore anticholinergic challenge does not appear to be a fruitful procedure for identifying patients with covert dyskinesia.



Author Affiliations



From the West-Ros-Park Mental Health Center, Hyde Park, Mass (Dr Gardos); McLean Hospital, Belmont, Mass (Dr Cole); LaBrie Associates, Cambridge, Mass (Dr LaBrie), the Dorchester Mental Health Center, Boston (Ms Baquelod); the Boston Mental Health Foundation, Brookline, Mass (Ms Moore); DIMES Inc, Watertown, Mass (Dr Sovner); and Lawrence and Memorial Hospital, New London, Conn (Mr Doyle). Dr Rapkin is in private practice in Guildford, Conn.


Footnotes



Accepted for publication Feb 23, 1984.

Reprint requests to Psychopharmacology Services, SB-III, McLean Hospital, 115 Mill St, Belmont, MA 02178 (Dr Gardos).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Spectrum of tardive syndromes: clinical recognition and management
Bhidayasiri and Boonyawairoj
Postgrad. Med. J. 2011;87:132-141.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.